Registry follow-up for ADA-SCID patients treated with Strimvelis
Part of Immune system & allergy clinical trials.
This study keeps track of people with ADA-SCID (a rare immune system condition) who previously received Strimvelis or a related treatment. It helps doctors understand long-term outcomes and safety after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child’s parent/guardian) must have ADA-SCID
- You must have been treated before with Strimvelis or GSK2696273 (or mPB-GT)
- Participants must be adults, or a parent/legal guardian must sign consent for a child
- You must be willing to join and be followed in a patient registry
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from adults with systemic AL amyloidosis to better understand the disease and outcomes. Because it includes pre-treatment records and follows people over time, it may help future patients by improving knowledge of how AL amyloidosis progresses and responds to care.
This study follows children and adults with SCID and related immune disorders to understand how the illness behaves over time. It also helps researchers learn which testing results and genetic types of SCID match different treatment plans.
This is a follow-up (no new treatment) study for people who previously received a gene therapy made from their own cells for ADA-SCID. It mainly tracks long-term safety and whether a marker showing the gene change can still be found.
This trial tests a new drug, STR-P005, for people with autoimmune diseases. It aims to see if the drug is safe and helps by targeting B cells that have a specific marker called CD19.
This early-phase study tests a new treatment called STR-P004 for people with certain aggressive B-cell lymphomas that have not responded to or returned after two or more prior treatments. The goal is to see if it is safe and effective.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Hear when a new Immunologic Deficiency Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.